Ikaria Steady State
Ikaria VCs looking for modest value boost in profitable biotech's IPO
The investors who formed Ikaria Inc. in 2007 through the combination of Ikaria Inc. and INO Therapeutics LLC aren't expecting much of a gain in valuation since the stock and cash deal valued the newco at $670 million. Last week, the company went on the road with an IPO that would value it at $710.6 million.
Ikaria updated its S-1 to sell 10 million shares at $15-$17. A $16 price would raise $160 million. The company filed in May to raise up to $200 million...